Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Chengdu Kanghong's KH815 enters human testing this month.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
AACR approaches, along with ASCO abstract titles.
A biliary tract cancer trial hits on response rate, but survival data will be key.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
